

Please amend the claims as follows:

Please cancel claims 2, 3, 11, 12, 17, 21, 22, and 34.

1. (Currently Amended) A homogeneous pharmaceutical composition in the form of single layer tablets or capsules which constitutes an oral controlled drug delivery system, comprising:

a drug selected from the group consisting of ciprofloxacin, acyclovir, diltiazem, ranitidine, captopril, and their pharmaceutically acceptable salts and esters,

a gas generating component,

a swelling agent present in an amount of from about 10% to about 50% by weight,

a viscosity enhancing agent, and

optionally a gel forming polymer, said pharmaceutical composition providing a combination of temporal and spatial control of drug delivery when ingested by a patient, for controlled release of the drug in the stomach or upper part of the small intestine.

2. Cancelled.

3. Cancelled

4. (Original) The pharmaceutical composition of claim 1 wherein the drug is present in an amount ranging from about 0.5 mg to 1200 mg.

5. (Original) The pharmaceutical composition of claim 1 wherein the gas generating component is a sulfite, a carbonate or a bicarbonate salt.

6. (Original) The pharmaceutical composition of claim 1 wherein the gas generating component is selected from the group consisting of sodium bicarbonate, potassium bicarbonate, sodium glycine carbonate, calcium carbonate, sodium sulfite, sodium bisulfite, and sodium metabisulfite.

7. (Original) The pharmaceutical composition of claim 1 wherein the gas generating component is a gas couple comprising a gas generating salt and an edible organic acid or a salt of an edible organic acid.

8. (Original) The pharmaceutical composition of claim 7 wherein the edible organic acid is selected from the group consisting of citric acid, ascorbic acid, tartaric acid, succinic acid, fumaric acid, malic acid, maleic acid, glycine, sarcosine, alanine, taurine, and glutamic acid.
9. (Original) The pharmaceutical composition of claim 1 wherein the gas generating component comprises about 5% to about 50% by weight of said composition.
10. (Original) The pharmaceutical composition of claim 1 wherein the gas generating component comprises about 10% to about 30% by weight of said composition.
11. Cancelled.
12. Cancelled.
13. Previously Cancelled
14. (Currently Amended) The pharmaceutical composition of claim [1] 51 wherein the swelling agent comprises about 10% to about 30% by weight of said composition.
15. (Currently Amended) The pharmaceutical composition of claim [1] 14 wherein the swelling agent comprises about 10% to about 20% by weight of said composition.
16. (Previously Amended) The pharmaceutical composition of claim 1 wherein the viscosity enhancing agent comprises a carbohydrate gum.
17. Cancelled.
18. (Currently Amended) The pharmaceutical composition of claim [1] 52 wherein the viscosity enhancing agent comprises about 0.1% to about 30% by weight of said composition.
19. (Currently Amended) The pharmaceutical composition of claim [1] 18 wherein the viscosity enhancing agent comprises about 0.1% to about 10% by weight of said composition.
20. (Currently Amended) The pharmaceutical composition of claim [1] 19 wherein the viscosity enhancing agent comprises about 0.1% to about 7% by weight of said composition.
21. Cancelled.
22. Cancelled.

23. (Currently Amended) The pharmaceutical composition of claim [1] 54 wherein the gel forming polymer is selected from the group consisting of sodium alginate, potassium alginate, ammonium alginate, and mixtures thereof.
24. (Currently Amended) The pharmaceutical composition of claim [1] 54 wherein the gel forming polymer comprises about 0.1% to about 20% by weight of said composition.
25. (Currently Amended) The pharmaceutical composition of claim [1] 24 wherein the gel forming polymer comprises about 0.1% to about 10% by weight of said composition.
26. (Currently Amended) The pharmaceutical composition of claim [1] 25 wherein the gel forming polymer comprises about 0.5% to about 5% by weight of said composition.
27. (Original) The pharmaceutical composition of claim 1 further comprising an additional hydrophilic water soluble polymer.
28. (Original) The pharmaceutical composition of claim 27 wherein the additional hydrophilic water soluble polymer is hydroxypropyl methylcellulose, hydroxypropylcellulose, polyacrylic acid, or mixtures thereof.
29. (Original) The pharmaceutical composition of claim 27 wherein the additional hydrophilic water soluble polymer comprises about 0.5% to about 20% by weight of said composition.
30. (Original) The pharmaceutical composition of claim 27 wherein the additional hydrophilic water soluble polymer comprises about 0.5% to about 10% by weight of said composition.
31. (Original) The pharmaceutical composition of claim 27 wherein the additional hydrophilic water soluble polymer comprises about 0.5% to about 5% by weight of said composition.
32. (Original) The pharmaceutical composition of claim 1 in the form of a tablet which is coated with a rapidly dissolving water soluble film forming polymer or a rapidly dissolving pharmaceutical excipient.

33. (Currently Amended) A homogeneous pharmaceutical composition in the form of single layer tablets or capsules for the controlled delivery of a drug, comprising:

the drug which is selected from the group consisting of ciprofloxacin, acyclovir, diltiazem, ranitidine, captopril, and their pharmaceutically acceptable salts and esters in an amount suitable for sustained release to a patient,

about 5 to about 50% by weight of a gas generating component,

about 10 to about 50% by weight of a swelling agent,

about 0.1% to about 30% by weight of a viscosity enhancing agent, and

optionally about 0.1% to about 20% by weight of a gel forming polymer, for controlled release of the drug in the stomach or upper part of the small intestine.

34. Cancelled.

35. (Original) The pharmaceutical composition of claim 33 wherein the drug is present in an amount ranging from about 0.5 mg to 1200 mg.

36. (Original) The pharmaceutical composition of claim 33 wherein the gas generating component is a sulfite, a carbonate or a bicarbonate salt.

37. (Original) The pharmaceutical composition of claim 33 wherein the gas generating component is selected from the group consisting of sodium bicarbonate, potassium bicarbonate, calcium carbonate, sodium sulfite, sodium bisulfite, sodium metabisulfite, and sodium glycine carbonate.

38. (Original) The pharmaceutical composition of claim 33 wherein the gas generating component includes an acid source which comprises about 0.5% to about 15% by weight of said composition.

39. (Original) The pharmaceutical composition of claim 38 wherein said acid source comprises an edible organic acid, a salt of an edible organic acid, or mixtures thereof.

40. (Original) The pharmaceutical composition of claim 33 wherein the swelling agent is selected from the group consisting of cross-linked polyvinylpyrrolidone, cross-linked carboxy-

methylcellulose sodium, and sodium starch glycolate.

41. (Previously Amended) The pharmaceutical composition of claim 33 wherein the viscosity enhancing agent, is selected from the group consisting of xanthan gum, tragacanth gum, gum karaya, guar gum, and acacia.

42. (Original) The pharmaceutical composition of claim 33 wherein the gel forming polymer is a water soluble salt of one or more polyuronic acids.

43. (Original) The pharmaceutical composition of claim 33 wherein the gel forming polymer is sodium alginate.

44. (Original) The pharmaceutical composition of claim 33 further comprising about 0.5% to about 20% by weight of an additional hydrophilic water soluble polymer.

45. (Original) The pharmaceutical composition of claim 44 wherein the additional hydrophilic water soluble polymer is selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropylcellulose, polyacrylic acid, and mixtures thereof.

46. (Original) The pharmaceutical composition of claim 33 in the form of a tablet which is coated with a rapidly dissolving water soluble film forming polymer or a rapidly dissolving pharmaceutical excipient.

47. Previously cancelled.

48. Previously cancelled.

49. Previously cancelled.

50. Previously cancelled.

Please introduce the following new claims:

51. (New) A homogeneous pharmaceutical composition in the form of single layer tablets or capsules which constitutes an oral controlled drug delivery system, comprising: a drug,  
a gas generating component,

a swelling agent selected from the group consisting of cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethylcellulose, and sodium starch glycolate, which is present in an amount of from about 10% to about 50% by weight, a viscosity enhancing agent, and

optionally a gel forming polymer, said pharmaceutical composition providing a combination of temporal and spatial control of drug delivery when ingested by a patient, for controlled release of the drug in the stomach or upper part of the small intestine.

52. (New) A homogeneous pharmaceutical composition in the form of single layer tablets or capsules which constitutes an oral controlled drug delivery system, comprising: a drug,

a gas generating component,

a swelling agent present in an amount of from about 10% to about 50% by weight,

a viscosity enhancing agent selected from the group consisting of xanthan gum, tragacanth gum, gum karaya, guar gum, and acacia, and

optionally a gel forming polymer, said pharmaceutical composition providing a combination of temporal and spatial control of drug delivery when ingested by a patient, for controlled release of the drug in the stomach or upper part of the small intestine.

53. (New) A homogeneous pharmaceutical composition in the form of single layer tablets or capsules which constitutes an oral controlled drug delivery system, comprising: a drug,

a gas generating component,

a swelling agent present in an amount of from about 10% to about 50% by weight,

a viscosity enhancing, and

optionally a gel forming polymer comprising a water soluble salt of at least one polyuronic acid, said pharmaceutical composition providing a combination of temporal and spatial control of drug delivery when ingested by a patient, for controlled release of the drug in the stomach or upper part of the small intestine.

54. (New) A homogeneous pharmaceutical composition in the form of single layer tablets or capsules which constitutes an oral controlled drug delivery system, comprising: a drug,

a gas generating component,

a swelling agent present in an amount of from about 10% to about 50% by weight,  
a viscosity enhancing, and

optionally a gel forming polymer comprising an alkali metal salt of alginic acid or pectic acid, said pharmaceutical composition providing a combination of temporal and spatial control of drug delivery when ingested by a patient, for controlled release of the drug in the stomach or upper part of the small intestine.